PMC7440848_01
Cytology of the bronchio-alveolar lavage fluid demonstrates abundant eosinophils, which appear as a light shade of pink in this stain.
dic-2020-5-3-g001.jpg
PMC7440848_01_dic-2020-5-3-g001.jpg
f1-dic-2020-5-3
The BALF revealed profound alveolar eosinophilia (86%), and the cytology of the BALF revealed abundant eosinophils without atypical cells (Figure 1).
This tissue obtained via transbronchial ultrasound-guided fine needle aspiration of a lymph node demonstrates fibrotic changes along the alveolar lining and eosinophils, which appear red in this stain.
dic-2020-5-3-g002.jpg
PMC7440848_01_dic-2020-5-3-g002.jpg
f2-dic-2020-5-3
The EBUS-TBNA of a lymph node revealed a heterogeneous lymphoid population and eosinophils consistent with a reactive lymph node (Figure 2).
This graph demonstrates the reduction in the level of serum IgE after the initiation of treatment for ICEP.
dic-2020-5-3-g003.jpg
PMC7440848_01_dic-2020-5-3-g003.jpg
f3-dic-2020-5-3
ICEP. In the first two and a half months after diagnosis when steroid monotherapy was employed, the patient had 22 healthcare encounters that were directly related to ICEP (Figure 3). Without an increase in compliance, she had dramatically decreased symptoms, serum IgE, peripheral eosinophilia, and healthcare utilization since starting mepolizumab (Figures 3-5).
This graph demonstrates the improvement in peripheral eosinophilia after treatment with mepolizumab. Although peripheral eosinophilia improved after initiation of prednisone, normalization of laboratory findings did not occur with prednisone monotherapy due to drug intolerance. The initiation of mepolizumab resulted in the sustained normalization of the patient's laboratory findings.. ICEP, idiopathic chronic eosinophilic pneumonia
dic-2020-5-3-g004.jpg
PMC7440848_01_dic-2020-5-3-g004.jpg
f4-dic-2020-5-3
Without an increase in compliance, she had dramatically decreased symptoms, serum IgE, peripheral eosinophilia, and healthcare utilization since starting mepolizumab (Figures 3-5).
This graph demonstrates the reduced requirement for healthcare visits that the patient experienced as a result of her symptom improvement after treatment with mepolizumab. All healthcare visits included in this graph occurred after the initiation of prednisone and were directly related to chronic eosinophilic pneumonia.
dic-2020-5-3-g005.jpg
PMC7440848_01_dic-2020-5-3-g005.jpg
f5-dic-2020-5-3
Without an increase in compliance, she had dramatically decreased symptoms, serum IgE, peripheral eosinophilia, and healthcare utilization since starting mepolizumab (Figures 3-5).